Skip to main content

Hyundai Pharmaceutical Co., Ltd. (004310.KS)

Boursa KuwaitView data quality →
52.6Fair

ValueMarkers Composite Index

Top 40%#26,651 of 44,714

DCF data not available

Piotroski
5/9
Neutral
Beneish
-2.52
Low Risk
Altman
1.33
Distress
DCF Value
-
N/A
ROIC
2.8%
Low
P/E
0.1
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Hyundai Pharmaceutical Co., Ltd. (004310.KS) — VMCI valuation read

004310.KS prints VMCI 53/100 inside the broad-market sample, where the median sits at 50. The 3-point above-median delta is the cleanest single-number summary of Hyundai Pharmaceutical Co., Ltd.'s composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.

On 004310.KS, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** 004310.KS trades at 18.0x earnings, 0% above the sector median of 18.0x; that is the value line. ROIC of 10.0% sits 0.0pp above the sector median (10.0%); that is the quality line. net debt to EBITDA of 0.6x leaves covenant headroom; that is the risk line for Hyundai Pharmaceutical Co., Ltd. on the trailing financials.

004310.KS rose 0.8% over the trailing 7 days, with a -16.8% read on a 30-day basis.

Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical equipment in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and eye vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. The company was founded in 1965 and is headquartered in Seoul, South Korea.

CEO: Sang-Jun Lee385 employeesKRwww.hyundaipharm.co.kr

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 004310.KS’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.